These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22704779)

  • 21. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia.
    Ryu J; Lee CW; Hong KH; Shin JA; Lim SH; Park CS; Shim J; Nam KB; Choi KJ; Kim YH; Han KH
    Cardiovasc Res; 2008 May; 78(2):333-40. PubMed ID: 18006432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Promoting effects and mechanisms of prostaglandin E1 on proliferation and migration of endothelial cells].
    Fu XY; Cai CQ; Zheng H; Li WY
    Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(3):222-5. PubMed ID: 23570600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model.
    Bhuvaneswari R; Yuen GY; Chee SK; Olivo M
    Lasers Surg Med; 2011 Sep; 43(7):651-62. PubMed ID: 22057493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
    Chen MC; Lee CF; Huang WH; Chou TC
    Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect.
    Tan WF; Zhang XW; Li MH; Yue JM; Chen Y; Lin LP; Ding J
    Eur J Pharmacol; 2004 Sep; 499(3):219-28. PubMed ID: 15381043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigallocatechin-3-gallate inhibits the PDGF-induced VEGF expression in human vascular smooth muscle cells via blocking PDGF receptor and Erk-1/2.
    Park JS; Kim MH; Chang HJ; Kim KM; Kim SM; Shin BA; Ahn BW; Jung YD
    Int J Oncol; 2006 Nov; 29(5):1247-52. PubMed ID: 17016658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells.
    Ma X; Ottino P; Bazan HE; Bazan NG
    Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2915-21. PubMed ID: 15326102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis.
    Chavakis T; Cines DB; Rhee JS; Liang OD; Schubert U; Hammes HP; Higazi AA; Nawroth PP; Preissner KT; Bdeir K
    FASEB J; 2004 Aug; 18(11):1306-8. PubMed ID: 15208269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-and interleukin-1beta-induced vascular permeability and angiogenesis in retinal endothelial cells.
    Sheikpranbabu S; Ravinarayanan H; Elayappan B; Jongsun P; Gurunathan S
    Vascul Pharmacol; 2010; 52(1-2):84-94. PubMed ID: 20006737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway.
    Li M; Wu S; Liu Z; Zhang W; Xu J; Wang Y; Liu J; Zhang D; Tian H; Li Y; Ye W
    Biochem Pharmacol; 2012 May; 83(9):1251-60. PubMed ID: 22305746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nobiletin, a citrus polymethoxyflavonoid, suppresses multiple angiogenesis-related endothelial cell functions and angiogenesis in vivo.
    Kunimasa K; Ikekita M; Sato M; Ohta T; Yamori Y; Ikeda M; Kuranuki S; Oikawa T
    Cancer Sci; 2010 Nov; 101(11):2462-9. PubMed ID: 20670297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo anti-angiogenic activities and inhibition of hormone-dependent and -independent breast cancer cells by ceramide methylaminoethylphosphonate.
    Chintalapati M; Truax R; Stout R; Portier R; Losso JN
    J Agric Food Chem; 2009 Jun; 57(12):5201-10. PubMed ID: 19476359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis.
    Lee M; Rodansky ES; Smith JK; Rodgers GM
    Microvasc Res; 2012 Sep; 84(2):109-15. PubMed ID: 22626948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-angiogenic activity of Ipomoea obscura extract and Ipobscurine-A.
    Hamsa TP; Kuttan G
    Immunopharmacol Immunotoxicol; 2011 Sep; 33(3):488-97. PubMed ID: 21058930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion.
    Keledjian K; Garrison JB; Kyprianou N
    J Cell Biochem; 2005 Feb; 94(2):374-88. PubMed ID: 15526277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tgf-beta antisense therapy increases angiogenic potential in human keratinocytes in vitro.
    Riedel K; Riedel F; Goessler UR; Germann G; Sauerbier M
    Arch Med Res; 2007 Jan; 38(1):45-51. PubMed ID: 17174722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lycopene inhibits angiogenesis in human umbilical vein endothelial cells and rat aortic rings.
    Elgass S; Cooper A; Chopra M
    Br J Nutr; 2012 Aug; 108(3):431-9. PubMed ID: 22142444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Newly synthesized quinazolinone HMJ-38 suppresses angiogenetic responses and triggers human umbilical vein endothelial cell apoptosis through p53-modulated Fas/death receptor signaling.
    Chiang JH; Yang JS; Lu CC; Hour MJ; Chang SJ; Lee TH; Chung JG
    Toxicol Appl Pharmacol; 2013 Jun; 269(2):150-62. PubMed ID: 23523585
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
    Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
    Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.